# US 2015/0031640 A1 · Antibacterial agents: combination of a rifamycin and a switch region inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031640 A1
- Document ID: US20150031640A1
- Status: Published application
- Kind: A1
- Application number: 14/376,789
- Filed: 2013-02-05
- Published: 2015-01-29
- Earliest claimed: 2012-02-06
- Assignees: Rutgers, The State University of New Jersey
- Inventors: Richard H. Ebright
- Web page: https://patentgrep.com/patent/US20150031640A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.

## Claims

### Claim 1

A composition comprising a rifamycin and a switch region inhibitor.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the rifamycin is selected from rifamycin A, rifamycin B, rifamycin C, rifamycin D, rifamycin E, rifamycin S, rifamycin SV, rifampin (rifampicin), rifapentine, rifabutin, rifamixin, and rifalazil.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the rifamycin is rifampin.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the switch region inhibitor is selected from a myxopyronin, a corallopyronin, a ripostatin, and a lipiarmycin.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the switch region inhibitor is a myxopyronin or a lipiarmycin.

### Claim 6 (depends on 1)

The composition of claim 1 further comprising a pharmaceutically acceptable diluent or carrier.

### Claim 7

A method of treating a bacterial infection in a mammal, reducing the minimum effective dose of at least one of a rifamycin and a switch region inhibitor in a mammal or reducing the spontaneous resistance frequency to at least one of a rifamycin and a switch region inhibitor in a mammal, comprising co-administering 1) a rifamycin and 2) a switch region inhibitor to the mammal.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 7)

The method of claim 7, wherein a composition comprising the rifamycin and the switch region inhibitor is administered.

### Claim 12

A method for inhibiting a bacterial RNA polymerase or for inhibiting the growth of a bacterium comprising contacting the bacterial RNA polymerase or bacterium in vitro or in vivo with 1) a rifamycin and 2) a switch region inhibitor.

### Claim 13

(canceled)

### Claim 14 (depends on 7)

The method of claim 7, wherein the rifamycin is selected from rifamycin A, rifamycin B, rifamycin C, rifamycin D, rifamycin E, rifamycin S, rifamycin SV, rifampin (rifampicin), rifapentine, rifabutin, rifamixin, and rifalazil, and pharmaceutically acceptable salts thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the rifamycin is rifampin.

### Claim 16 (depends on 7)

The method of claim 7, wherein the switch region inhibitor is selected from a myxopyronin, a corallopyronin, a ripostatin, and a lipiarmycin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the switch region inhibitor is a myxopyronin or a lipiarmycin.

### Claim 18 (depends on 12)

The method of claim 12, wherein the bacterium is a Gram-positive bacterium.

### Claim 19 (depends on 12)

The method of claim 12, wherein the bacterium is a Gram-negative bacterium.

### Claim 20 (depends on 12)

The method of claim 12, wherein the bacterium is Staphylococcus aureus, Mycobacterium tuberculosis, or Escherichia coli.

### Claim at position 19

21-43. (canceled)

### Claim 44 (depends on 7)

The method of claim 7, wherein the bacterial infection is treated without treatment failure due to spontaneous resistance.

### Claim 45 (depends on 12)

The method of claim 12, wherein the rifamycin is selected from rifamycin A, rifamycin B, rifamycin C, rifamycin D, rifamycin E, rifamycin S, rifamycin SV, rifampin (rifampicin), rifapentine, rifabutin, rifamixin, and rifalazil, and pharmaceutically acceptable salts thereof.

### Claim 46 (depends on 12)

The method of claim 12, wherein the switch region inhibitor is selected from a myxopyronin, a corallopyronin, a ripostatin, and a lipiarmycin.

### Claim 47 (depends on 12)

The method of claim 12, wherein the rifamycin is rifampin and/or the switch region inhibitor is a myxopyronin or a lipiarmycin.
